Position
Parallel Advisors, LLC in Arcus Biosciences, Inc.
Back to the book · All holders of RCUS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$193K$23.83 → $21.60
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 86.6K | $2.06M | — | — | — | 0.0% |
| Q1 2026 | 86.6K | $1.87M | $21.60 | −$193K | $0 | 0.0% |